国产精品视频一区二区三区四,亚洲av美洲av综合av,99国内精品久久久久久久,欧美电影一区二区三区电影

上海富雨生物科技有限公司
初級(jí)會(huì)員 | 第1年

18956075901

當(dāng)前位置:上海富雨生物科技有限公司>>細(xì)胞庫 / 細(xì)胞培養(yǎng)>>普通細(xì)胞>> SNU-398人肝癌細(xì)胞(附S

SNU-398人肝癌細(xì)胞(附S

參  考  價(jià)面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號(hào)

品       牌

廠商性質(zhì)生產(chǎn)商

所  在  地

更新時(shí)間:2025-02-11 18:16:16瀏覽次數(shù):65次

聯(lián)系我時(shí),請(qǐng)告知來自 化工儀器網(wǎng)
同類優(yōu)質(zhì)產(chǎn)品更多>
人肝癌細(xì)胞SNU-398種屬人別稱SNU398; NCI- SNU- 39 8組織來源肝臟疾病肝細(xì)胞癌傳代比例/細(xì)胞消化1:2傳代 ,消化1-3分鐘,培養(yǎng)基配置RPMI1640 培養(yǎng)基: 10%胎牛血清

人肝癌細(xì)胞SNU-398

種屬
別稱SNU398; NCI- SNU- 39 8
組織來源肝臟
疾病肝細(xì)胞癌
傳代比例/細(xì)胞消化1:2傳代 ,消化1-3分鐘 ,
培養(yǎng)基配置RPMI1640 培養(yǎng)基: 10%胎牛血清 1%雙抗
簡(jiǎn)介SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韓國(guó)患者的間變性肝細(xì)胞癌 ,該患者已通過脂質(zhì)體加 和-C 的組合進(jìn)行了經(jīng)導(dǎo)管動(dòng)脈栓塞治療。既可以附著細(xì)胞也可以懸浮細(xì)胞。懸浮的細(xì)胞是可行 ,不應(yīng)丟 棄。通過溫和離心 (125 xg) 回收懸浮細(xì)胞 ,以與貼壁細(xì)胞群一起進(jìn)行繼代培養(yǎng)。
形態(tài)上皮細(xì)胞樣
生長(zhǎng)特征懸浮貼壁生長(zhǎng)
倍增時(shí)間每周 2 3
抗原表達(dá)Blood Type O; Rh +
STRAmelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18
保藏機(jī)構(gòu)ATCC; CRL- 2233

Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.

Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.



untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern

會(huì)員登錄

×

請(qǐng)輸入賬號(hào)

請(qǐng)輸入密碼

=

請(qǐng)輸驗(yàn)證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~
撥打電話
在線留言
调兵山市| 财经| 东港市| 峨眉山市| 连平县| 平谷区| 冀州市| 泽库县| 大足县| 融水| 阳新县| 泌阳县| 景东| 晋宁县| 芜湖市| 谢通门县| 上林县| 苍山县| 大同县| 米易县| 互助| 喀什市| 会昌县| 留坝县| 萨迦县| 镇安县| 潼南县| 高密市| 莲花县| 如东县| 油尖旺区| 建水县| 桑日县| 清流县| 建平县| 米泉市| 盱眙县| 仲巴县| 兴国县| 同德县| 乌拉特中旗|